Panobinostat Regimen Yields Benefit for R/R Myeloma After Frontline ASCT
February 23rd 2023Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.
UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support
Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral